(MENAFNEditorial) iCrowdNewswire - Nov 20, 2017
research is provided on past, current and anticipated market situations, market drivers, trends driving it, and the challenges faced by the market which will help in deciding corporate strategy, product strategy, marketing strategy and sales strategy. Industry experts project Dyslipidemia Drugs market to grow at a CAGR of 5.27% during the period 2017-2021.
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
Firstly, the Dyslipidemia Drugs market research report provides a basic overview of the industry including definitions, market status and industry chain structure. The Dyslipidemia Drugs market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status. What's more, the Dyslipidemia Drugs industry development trends and growth patterns are analyzed.
Request a sample of Dyslipidemia Drugs market research report @
Dyslipidemia Drugs market potential is analysed for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, demand and present scenarios in Dyslipidemia Drugs industry. To determine the Dyslipidemia Drugs market size the report considers detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. Further the Dyslipidemia Drugs market report focuses on global major leading industry players with information. Report contains vendor landscape in addition to a SWOT analysis of the key vendors operating in Dyslipidemia Drugs market space like AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals and many more.
Dyslipidemia Drugs Market Drivers, Challenges and Trends: –
Dyslipidemia Drugs Market Driver: – one driver in market is increasing risk of CVDs. Elevated levels of cholesterol in the blood lead to the deposition of cholesterol in the arterial walls, which results in atherosclerosis, hardening and narrowing the arteries. The resultant narrowing of blood vessels decreases the blood flow to the heart muscles, causing a heart attack. High cholesterol levels account for nearly one-third of all ischemic heart diseases and hence, remain a significant cause of ischemic heart diseases and strokes in developed and developing countries such as India and China. Data estimates suggest that among men aged 40 years and over, a 10% decrease in serum cholesterol levels reduces the risk of heart disease by 50% within five years. Hence, cardiovascular risk management guidelines by authorities such as the American College of Cardiology and American Heart Association consider reducing blood cholesterol an important factor in reducing cardiovascular risk. As cholesterol disorder is one of the major causes for CVDs, patients try to strictly adhere to cholesterol maintaining drugs to avoid the occurrence of CVD. This preventive approach toward the occurrence of CVDs will further boost the sales of cholesterol controlling agents.
Dyslipidemia Drugs Market Challenge: – one challenge in market is drawbacks associated with current therapies. Statins are prescribed drugs for lowering LDL-C levels and constitute the first line of therapy for hypercholesterolemia. However, long-term administration and the muscle-related side effects of statins lead to poor patient compliance. Doubling the dose of statins might increase drug toxicity with a negligible increase in LDL-lowering effects. Furthermore, in February 2012, the FDA announced that statins could be associated with side effects such as cognitive effects and hyperglycemia. Bile acid sequestrates lead to side effects related to the gastrointestinal tract. Niacin-based formulations are generally associated with flushing and hepatotoxicity. Fibrates are associated with an increased risk of cholesterol gallstones and side effects related to the gastrointestinal tract. Thus, there is a high demand for lipid-lowering drugs with a good safety profile.
Dyslipidemia Drugs Market trend: – One trend in market is increasing use of statins. Statins dominate the global dyslipidemia drugs market. Statins are reported to be the most effective among all dyslipidemia drugs in lowering the risk of heart attacks. The ATP IV guidelines, which are based on data from randomized controlled trials, strongly recommend the use of statins to manage atherosclerotic CVD. The ATP IV guidelines have identified four treatment groups for statins and have recommended treatment based on intensity groups. For instance, it recommends the use of high-intensity statins in individuals with established atherosclerotic CVD. The other two intensity groups include moderate-intensity statin therapy and low-intensity statin therapy. Furthermore, the ATP IV panel found no evidence in support of using non-statin cholesterol-lowering drugs in individuals with statin intolerance or as a component of combination therapy. Moreover, the current ATP guidelines might not support the use of non-statin therapy in statin-tolerant patients
We even do customized reports for our customers; we can add the list of manufacturers or application type or product types that you need in the report. Ask for it @
Market segmentation by drug class:- Statins, Cholesterol absorption inhibitors, Dyslipidemia injectables, Others ; Geographic Segmentation: – Americas, APAC, EMEA
In the next part of Dyslipidemia Drugs market research report, development policies and plans are discussed. This report also states growing domain, production and revenue by regions. The Dyslipidemia Drugs Market forecast to 2021 Considering Market Size, Sales, Revenue, Growth rate, Price and Trends for Regions, Types and Applications is also provided.
MENAFN2011201700703403ID1096119039
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.